Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic ...

When you start a medication like Dupixent (dupilumab), you expect relief from eczema or asthma, not the devastation of a cancer diagnosis. Yet ...

BIOTA Labs, an emerging medical food company revolutionizing medical nutrition for the management of gastrointestinal (GI) conditions, announced that four clinical studies leveraging mBIOTA ...

An anti-inflammation injectable drug called dupilumab can reduce mucus buildup and improve breathing among asthma patients, a ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab-treated patients with AD were 4.1003 times more likely to develop cutaneous T-cell lymphoma vs. those ...

Omalizumab had the greatest risk for adverse effects and dupilumab had the most favorable safety profile among biologics for patients with asthma, according to an abstract presented at the CHEST ...

Compared with placebo, dupilumab treatment resulted in statistically significant and meaningful symptom improvements in adults and adolescents with eosinophilic esophagitis (EoE), according to ...

PHOENIX -- Nearly three-fifths of patients with eosinophilic esophagitis (EoE) achieved remission after treatment with dupilumab (Dupixent), researchers reported. In a 6-month study, 58.8% of adults ...

Compared with dupilumab, a significantly higher proportion of patients treated with upadacitinib achieved both EASI 90 and WP-NRS 0/1 at week 16. Among patients with moderate to severe atopic ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window PHOENIX -- ...

A comparison of type 2 biologics indicated for the treatment of chronic rhinosinusitis with nasal polyps identified dupilumab as the most effective drug in decreasing nasal polyp score and nasal ...

VANCOUVER, Canada — New evidence from the phase 3 EoE KIDS trial supports the safety and efficacy of dupilumab (Dupixent) treatment for children aged 1-11 years with eosinophilic esophagitis (EoE).